[Somatostatin analogs with lutetium-177 in neuroendocrine tumors]
Gonzalez L, Augustovski F, Alcaraz A, Pichon-Riviere A, García Martí S, Bardach A, Ciapponi A.
Record ID 32018001580
Spanish
Original Title:
Análogos de la somatostatina con Lutecio-177 en tumores neuroendócrinos
Authors' recommendations:
Moderate-quality evidence suggests that the use of lutetium-177-radiolabeled somatostatin analogs in patients with advanced well-differentiated gastroenteropancreatic neuroendocrine tumors with somatostatin receptor overexpression and who progressed to first-line therapy, improves overall survival, progression-free survival and objective response rate when compared with the use of high-dose lanreotide. Evidence obtained from network meta-analysis shows that its efficacy might be superior to everolimus use in this group of patients.
Low-quality evidence suggests that the use of lutetium-177-radiolabeled somatostatin analogs in patients with advanced neuroendocrine tumors with somatostatin receptor overexpression of different etiology might show the same benefit.
Its use is mentioned among the treatment options as second-line therapy in clinical practice guidelines from the main international societies. In addition, most public and private health funders from high-income countries consider its use in some cases after reaching an agreement on the sale price.
Details
Project Status:
Completed
Year Published:
2020
URL for published report:
https://www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Somatostatin
- Receptors, Somatostatin
- Carcinoma, Neuroendocrine
- Neuroendocrine Tumors
- Lutetium
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.